The development of epidermal growth factor receptor (EGFR) selective tyrosine kinase inhibitors, Gefitinib and Erlotinib, has opened a line of study to improve the treatment of patients with advanced stages of NSCLC who have failed standard chemotherapy regimens. However, in the light of the latest published results, there are no reasons to use Gefitinib for the treatment of patients in whom drug response has not previously been demonstrated.